RENB
Lunai Bioworks Inc.
Set alert
- YTD
- +69.25%
- 1 year
- +69.25%
- Open
- 1.19
- Prev close
- 1.42
- Mkt cap
- 177.76M
- Vol
- 808.78K
- Avg vol
- 813.16K
- EPS
- -0.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.19
- High
- 1.42
- Forward P/E
- 0.00
- Beta
- 0.54
- Short ratio
- 4.72
- Inst. own
- 9.36%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.87564
- 200-d avg
- 1.28
- 1y target
- 0.00
Key statistics
- Market cap
- 177.76M
- Enterprise value
- 94.97M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.32
- EPS (TTM)
- -0.98
- Beta
- 0.54
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 7.58M
- Total cash
- 220.47K
- Total debt
- 4.02M
- Return on equity
- -90.38%
- Shares outstanding
- 158.72M
- Short % of float
- 2.85%
- 50-day average
- 0.87564
- 200-day average
- 1.28
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
About Lunai Bioworks Inc.
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- renovarobio.com
News
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships
- Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split
- Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics
- Top 3 Health Care Stocks You'll Regret Missing In Q3
- Lunai Bioworks Inc. Retains American Defense International
- Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks
- Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector
Your note
Sign in to keep a note on RENB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABILDGAARD OLE | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 12, 2024 | 0 |
| MILLER AVRAM | Director | Stock Award(Grant) | Oct 22, 2023 | 1,000,000 |
| SINDLEV RENE | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Feb 19, 2024 | 0 |
| WEINSTEIN DAVID HERSHEL | Chief Executive Officer | Stock Award(Grant) | Oct 13, 2024 | 250,000 |
| WILLIAM ANDERSON WITTEKIND | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 28, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 14.75% | 5,719,603 | 6.41M | Sep 29, 2024 |
| Blackrock Inc. | 9.32% | 3,613,702 | 4.05M | Sep 29, 2024 |
| Geode Capital Management, LLC | 4.05% | 1,572,290 | 1.76M | Sep 29, 2024 |
| State Street Corporation | 3.41% | 1,323,832 | 1.48M | Sep 29, 2024 |
| Northern Trust Corporation | 1.53% | 594,889 | 666.27K | Sep 29, 2024 |
| Morgan Stanley | 0.92% | 356,658 | 399.46K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 8.62% | 3,341,900 | 3.74M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 4.82% | 1,869,825 | 2.09M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 3.03% | 1,175,285 | 1.32M | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 1.29% | 500,399 | 560.45K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 1.20% | 465,175 | 521.00K | Oct 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.67% | 258,842 | 289.90K | Oct 30, 2024 |